Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards

NCT ID NCT07739121

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boards provide treatment plans. The plans are scored for agreement with established guidelines and for potential harm. The goal is to see if AI can reliably support cancer treatment decisions, not to replace human experts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Frontier large language models (AI) compared with multidisciplinary tumour board recommendations
What this could lead to
If AI matches expert tumor boards, it could support doctors in making consistent, guideline-based cancer treatment decisions, potentially improving care quality and accessibility.
What could go wrong
This is a non-interventional benchmark using synthetic cases, not real patients. AI may still make dangerous errors, and results may not reflect real-world clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTIFICAL INTELLIGENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hopital Européen Georges Pompidou

    RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.